CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary
Authors:
- 6 December 2012
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 139 (4) , 551-556
Abstract
A challenge in management of breast cancer is the development of brain metastases (BM). Because of improvements in systemic therapy with longer survival of patients with advanced cancer, BM can appear at a time when extra-BM disease is under control. Development of potential preventive strategies are considered, and new developments in systemic approaches to treatment of BM, (cytotoxic/targeted therapy), are explored. In primary breast cancer, ER/PR, HER2 are important biological markers for predicting prognosis and making effective treatment decisions. Known are changes in markers due to metastases, but clinical significance is still unclear. Aim of this retrospective study is to detect changes in immunohistochemical markers of primary and BM, to recognize concordance and impact on prognosis. Twenty-one consecutive primary breast cancer patients who developed BM and got surgical resection of BM were enrolled in this study. Matched-pair analyses of primary and BM were done with evaluation by immunostaining (ER, PR, HER2). Loss of ER/PR receptor positivity was seen in BM compared to primary (ER: 47.6 %/9.0 %; PR: 42.9 %/0 %), respectively. High concordance exists for HER2 status in primary and BM (>80 %). HER2-positive breast cancer had a shorter median interval until appearance of metastases than HER2-negative patients (32.1/39 months; p = n.s.). With loss of receptor positivity (ER/PR) in BM treatment, decisions are very difficult. High concordance of HER2 status was seen in matched-pair analysis. Further studies had to investigate whether HER3/4 is a possible target for further therapy.Keywords
This publication has 34 references indexed in Scilit:
- Molecular Aspects of Breast Cancer Metastasis to the BrainGenetics Research International, 2011
- The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastasesCancer, 2010
- Estrogen and HER-2 Receptor Discordance Between Primary Breast Cancer and MetastasisThe Oncologist, 2010
- HER3 and downstream pathways are involved in colonization of brain metastases from breast cancerBreast Cancer Research, 2010
- Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based ReviewJournal of Clinical Oncology, 2010
- Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?Annals of Oncology, 2009
- Survival among women with triple receptor-negative breast cancer and brain metastasesAnnals of Oncology, 2009
- Defining prognosis for women with breast cancer and CNS metastases by HER2 statusAnnals of Oncology, 2008
- Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)Annals of Oncology, 2006
- Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study GroupJournal of Clinical Oncology, 2005